Author/Editor | Juhan-Vague, I; Alessi, MC; Morange, PE | |
Title | Hypofibrinolysis and increased PAI-I are linked to atherothrombosis via insulin resistance and obesity | |
Type | članek | |
Source | In: Pathophysiological, clinical and laboratory aspects of thromboembolic disease. Proceedings of the 8th advanced teaching course in thrombosis and haemostasis; 2001 Mar 22-27; Kranjska gora. Ljubljana: University medical center, Department of angiology, | |
Publication year | 2001 | |
Volume | str. 115-23 | |
Language | eng | |
Abstract | Plasminogen activator inhibitor 1 (PAI-1) is the primary physiological inhibitor of plasminogen activation in vivo. Circulating PAI-1 levels are elevated in patients with coronary heart disease and may play an important role in the development of atherothrombosis by decreasing fibrin degradation. Increased PAI-1 expression can also directly influence vessel wall remodelling. Prospective cohort studies have underlined the, association between increased plasma PAI-1 levels and the risk of coronary events, -but .the predictive capacity of PAI-1 disappeared after adjustments for insulin resistance markers. The insulin resistance syndrome, which is characterized partly by obesity with visceral fat accumulation, is considered as a major regulator of PAI-1 expression. Recently, production of PAI-l by adipose tissue; in particular by fat from omentum, has been evidenced, and it has been proposed that it could be responsible for the elevated plasma PAI-1 level observed in insulin resistance. The role of stroma cells; tumour necrosis factor (TNF)-alpha and transforming growth factor (TGF)-beta as possible enhancers of PAI-1 synthesis are presently emphasized. Glucocorticoids and insulin may also be implicated. Moreover, a weak genetic control of plasma PAI-1 concentration has been described in patients with. high plasma levels of PAI-1. The role of PAI-1 in the. development of adipose tissue metabolism is important to consider as PAI-1 -/- mice submitted to a high-fat diet showed changes in cell composition of adipose tissue and in plasma insulin and triglyceride levels. | |
Descriptors | PLASMINOGEN ACTIVATOR INHIBITOR 1 FIBRINOLYSIS ATHEROSCLEROSIS THROMBOSIS INSULIN RESISTANCE OBESITY POLYMORPHISM (GENETICS) |